Kalaris Therapeutics, Inc. 8-K

What Happened
Kalaris Therapeutics (KLRS) filed an 8-K on July 17, 2026 disclosing a press release and updated corporate presentation with positive additional data from expanded cohorts in its Phase 1a single ascending dose (SAD) trial of TH103 for treatment‑naïve neovascular age‑related macular degeneration (nAMD). The expanded dataset includes 17 treatment‑naïve patients and 3 treatment‑experienced patients (20 total), all with six months of follow‑up.

Key Details

• Expanded Phase 1a SAD cohort: 17 treatment‑naïve + 3 treatment‑experienced patients; all 20 completed 6 months follow‑up.
• Efficacy at one month (treatment‑naïve): mean +9.2 letters BCVA; mean −118 µm central subfield thickness; mean 93% reduction in central intraretinal fluid.
• Durability/time to retreatment (after single injection, treatment‑naïve N=17): 41% first retreatment at ≥4 months; 35% at ≥5 months; 29% required no additional anti‑VEGF during 6 months. Treatment‑experienced (N=3) showed ~2‑month extension vs prior intervals.
• Pharmacokinetics and safety: TH103 plasma Cmax was 27–53× lower on a molar basis vs leading anti‑VEGF agents; no intraocular inflammation (IOI) among six patients dosed at 2.5 mg with product made after impurity‑reducing process changes (one prior transient IOI at 5 mg resolved).
• Corporate update: company is enrolling/dosing in an ongoing Phase 1b/2 study (four‑dose loading regimen, ascending dose) and remains on track to share initial Phase 1b/2 data in H1 2027.

Why It Matters
For investors, these results provide early clinical evidence that TH103 may produce meaningful vision and retinal‑anatomy improvements with signals of extended durability after a single dose—potentially affecting treatment frequency if confirmed. The data support continued development (Phase 1b/2 ongoing) and will inform dose selection for potential Phase 3 trials. The company’s filing also includes the usual forward‑looking statement cautions: results are early, and future outcomes and timelines remain subject to clinical, regulatory, manufacturing, and financial risks.